ArticlePediatric blood & cancer2021

In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium.

Raushan T Kurmasheva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.